320 related articles for article (PubMed ID: 29084827)
1. Prospective Evaluation of
Minamimoto R; Sonni I; Hancock S; Vasanawala S; Loening A; Gambhir SS; Iagaru A
J Nucl Med; 2018 May; 59(5):803-808. PubMed ID: 29084827
[No Abstract] [Full Text] [Related]
2. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
3. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
[TBL] [Abstract][Full Text] [Related]
4. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
5. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
6. Prospective Comparison of
Duan H; Song H; Davidzon GA; Moradi F; Liang T; Loening A; Vasanawala S; Iagaru A
J Nucl Med; 2024 Jun; 65(6):897-903. PubMed ID: 38664016
[TBL] [Abstract][Full Text] [Related]
7.
Duan H; Moradi F; Davidzon GA; Liang T; Song H; Loening AM; Vasanawala S; Srinivas S; Brooks JD; Hancock S; Iagaru A
Lancet Oncol; 2024 Apr; 25(4):501-508. PubMed ID: 38423030
[TBL] [Abstract][Full Text] [Related]
8. A Pilot Study of
Duan H; Ghanouni P; Daniel B; Rosenberg J; Thong A; Kunder C; Aparici CM; Davidzon GA; Moradi F; Sonn GA; Iagaru A
J Nucl Med; 2023 May; 64(5):744-750. PubMed ID: 36396456
[TBL] [Abstract][Full Text] [Related]
9. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
10. Correlation of
Duan H; Baratto L; Fan RE; Soerensen SJC; Liang T; Chung BI; Thong AEC; Gill H; Kunder C; Stoyanova T; Rusu M; Loening AM; Ghanouni P; Davidzon GA; Moradi F; Sonn GA; Iagaru A
J Nucl Med; 2022 Dec; 63(12):1829-1835. PubMed ID: 35552245
[No Abstract] [Full Text] [Related]
11. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
12. Value of
Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Comparison of the
Koller L; Joksch M; Schwarzenböck S; Kurth J; Heuschkel M; Holzleitner N; Beck R; von Amsberg G; Wester HJ; Krause BJ; Günther T
J Nucl Med; 2023 Oct; 64(10):1654-1659. PubMed ID: 37934025
[TBL] [Abstract][Full Text] [Related]
14. A Pilot Study of
Duan H; Ghanouni P; Daniel B; Rosenberg J; Davidzon GA; Aparici CM; Kunder C; Sonn GA; Iagaru A
J Nucl Med; 2023 Apr; 64(4):592-597. PubMed ID: 36328488
[TBL] [Abstract][Full Text] [Related]
15. PET Imaging Using Gallium-68 (
Duan H; Iagaru A
PET Clin; 2022 Oct; 17(4):621-629. PubMed ID: 36153233
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of fully hybrid [
Ghezzo S; Mapelli P; Samanes Gajate AM; Palmisano A; Cucchiara V; Brembilla G; Bezzi C; Suardi N; Scifo P; Briganti A; De Cobelli F; Chiti A; Esposito A; Picchio M
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):907-918. PubMed ID: 37897615
[TBL] [Abstract][Full Text] [Related]
18. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
[TBL] [Abstract][Full Text] [Related]
19. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]